NeoGenomics has exercised its option to buy Inivata, a precision cancer diagnostics company that was formed to exploit Cambridge and CRUK research seven years ago.
Inivata, a UK-based precision cancer diagnostics spinout of University of Cambridge and Cancer Research UK, agreed to an acquisition by cancer diagnostics service provider NeoGenomics for $390m today.
NeoGenomics had supplied a $25m initial series C tranche in May 2020 as part of a strategic collaboration agreement that gave the corporate a fixed price option to purchase the spinout.
Founded in 2014, Inivata has created a liquid biopsy platform that can extract genomic information from a simple…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
